Filtered By:
Specialty: Pharmaceuticals
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 890 results found since Jan 2013.
Median Door-in-Door-Out Time 174 Minutes for Interhospital Stroke Transfer
THURSDAY, Aug. 17, 2023 -- For patients with interhospital transfer for acute stroke, the median door-in-door-out time is 174 minutes, which is longer than current recommendations, according to a study published in the Aug. 15 issue of the Journal...
Source: Drugs.com - Pharma News - August 17, 2023 Category: Pharmaceuticals Source Type: news
Early Antiplatelet Therapy With Mechanical Thrombectomy Shows Benefits
TUESDAY, Aug. 15, 2023 -- Early use of antiplatelet treatment after mechanical thrombectomy (MT) for acute ischemic stroke is associated with better functional outcomes without safety concerns, according to a study presented at the annual meeting of...
Source: Drugs.com - Pharma News - August 15, 2023 Category: Pharmaceuticals Source Type: news
Disparities in Stroke Risk Factors Persist for Black Adults
MONDAY, Aug. 7, 2023 -- After one year of intensive medical management, certain risk factors associated with stroke are reduced among Black adults, according to a study published online Aug. 3 in Stroke.
Eyad Almallouhi, M.D., from the Medical...
Source: Drugs.com - Pharma News - August 7, 2023 Category: Pharmaceuticals Source Type: news
Incidence of Ischemic Stroke in Seniors Not Reduced by Low-Dose Aspirin
FRIDAY, July 28, 2023 -- For healthy older adults, low-dose aspirin does not reduce the risk for ischemic stroke but is associated with an increased risk for intracranial bleeding, according to a study published online July 26 in JAMA Network...
Source: Drugs.com - Pharma News - July 28, 2023 Category: Pharmaceuticals Source Type: news
Women With LVO Acute Ischemic Stroke Less Likely to Be Routed to Stroke Centers
WEDNESDAY, July 26, 2023 -- Women with large vessel occlusion (LVO) acute ischemic stroke (AIS) are less likely to be routed to comprehensive stroke centers (CSCs) compared with men, despite presenting with more significant stroke syndromes,...
Source: Drugs.com - Pharma News - July 26, 2023 Category: Pharmaceuticals Source Type: news
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
MRI May Be Preferred to CT With CT Angiography Alone for Dizziness in ED
THURSDAY, July 13, 2023 -- For patients presenting to the emergency department with dizziness, magnetic resonance imaging (MRI) may be preferred to computed tomography (CT) with CT angiography (CTA) alone in terms of stroke management, according to...
Source: Drugs.com - Pharma News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
P2Y ₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease
MONDAY, July 10, 2023 -- For patients with coronary artery disease (CAD), P2Y12 inhibitor monotherapy is associated with a lower risk for cardiovascular death, myocardial infarction, and stroke compared with aspirin monotherapy, according to a study...
Source: Drugs.com - Pharma News - July 10, 2023 Category: Pharmaceuticals Source Type: news
Ticagrelor-Acetylsalicylic Acid More Beneficial for Obese With Minor Stroke, TIA
MONDAY, July 10, 2023 -- For patients with minor stroke or transient ischemic attack (TIA) who carry the CYP2C19 loss-of-function allele, those with obesity receive more clinical benefit from ticagrelor-acetylsalicylic acid (ASA) than...
Source: Drugs.com - Pharma News - July 10, 2023 Category: Pharmaceuticals Source Type: news
Append Medical Raises $4.35M in Initial Closing of Extended Series A Round
Funds will be used to complete the development of and support the First-in-Human Study of the Appligator for the Prevention of Stroke in Atrial Fibrillation Patients
OR YEHUDA, Israel, July 6, 2023 -- (Healthcare Sales & Marketing Network) -- Append M... Devices, Interventional, Cardiology, Venture Capital Append Medical, Appligator, left atrial appendage, Atrial Fibrillation
Source: HSMN NewsFeed - July 6, 2023 Category: Pharmaceuticals Source Type: news
Uncontrolled Heart Risk Factors Common in Head, Neck Squamous Cell Cancer
THURSDAY, June 29, 2023 -- The burden of suboptimally controlled cardiovascular (CV) risk factors and incident risk of stroke and myocardial infarction (MI) are considerable in patients with head and neck squamous cell carcinoma (HNSCC), according...
Source: Drugs.com - Pharma News - June 29, 2023 Category: Pharmaceuticals Source Type: news
DiaMedica Therapeutics raises $37.5 million for stroke and kidney treatment
DiaMedica Therapeutics Inc. said Monday it raised $37.5 million through a private placement deal selling 11 million common shares.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 26, 2023 Category: Pharmaceuticals Authors: Alyxandra Sego Source Type: news
